This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
The company’s main area of focus is cystic fibrosis (CF). The company’s lead marketed products are Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor), Symdeko/Symkevi (tezacaftor in combination with ivacaftor), Orkambi (lumacaftor in combination with ivacaftor) and Kalydeco (ivacaftor), which are collectively approved to treat the majority of the people with CF in North America, Europe and Australia. Trikafta, Vertex’s triple combination regimen, was approved by the FDA in October 2019 for the treatment of CF in people aged 12 years and older who have at least one F508del mutation. Kaftrio (brand name of Trikafta in EU) was approved in the European Union in August 2020. It is also being evaluated in younger patients in the United States. With approval of Trikafta, Vertex can address a significantly larger CF patient population — almost 90% of patients with CF — in the future. Meanwhile, Vertex is pursuing genetic therapies to address the remaining 10% of CF patients. While CF remains the main area of focus, Vertex is also developing treatments for sickle cell disease, thalassemia and pain management.
Top Stock Reports for McDonald's, Deere & Marsh & McLennan
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including McDonald's Corporation (MCD), Deere & Company (DE) and Marsh & McLennan Companies, Inc. (MMC).
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
CRISPR (CRSP) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
On CRISPR's (CRSP) first-quarter earnings call, investors will likely focus on its pipeline, especially its lead candidate exa-cel, due to the absence of marketed drugs.
Vertex (VRTX) Q1 Earnings Top Estimates, Revenues Up Y/Y
by Zacks Equity Research
Vertex Pharmaceuticals' (VRTX) first-quarter 2023 earnings and sales beat estimates. Management reiterates financial guidance for 2023.
Vertex Pharmaceuticals (VRTX) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Vertex (VRTX) delivered earnings and revenue surprises of 3.39% and 3.02%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
ImmunoGen (IMGN) Q1 Earnings Beat, Elahere Uptake Encouraging
by Zacks Equity Research
ImmunoGen (IMGN) reports impressive Q1 earnings results on strong adoption of sole-marketed drug Elahere. The company raises financial guidance for 2023. Post the news, shares moved up 25%.
Strength Seen in Vertex (VRTX): Can Its 5.0% Jump Turn into More Strength?
by Zacks Equity Research
Vertex (VRTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Cytek Biosciences, Inc. (CTKB) Soars 13.4%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Cytek Biosciences, Inc. (CTKB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Vertex Pharmaceuticals (VRTX) Stock Moves -0.27%: What You Should Know
by Zacks Equity Research
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $331.93, marking a -0.27% move from the previous day.
Will Rhythm Pharmaceuticals, Inc. (RYTM) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Rhythm Pharmaceuticals, Inc. (RYTM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $332.84, moving +0.53% from the previous trading session.
Earnings Preview: Vertex Pharmaceuticals (VRTX) Q1 Earnings Expected to Decline
by Zacks Equity Research
Vertex (VRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Analyst Blog Highlights Linde, Vertex Pharmaceuticals, Edwards Lifesciences, General Motors and MSCI
by Zacks Equity Research
Linde, Vertex Pharmaceuticals, Edwards Lifesciences, General Motors and MSCI are included in this Analyst Blog.
Top Stock Reports for Linde, Vertex Pharmaceuticals & Edwards Lifesciences
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Linde plc (LIN), Vertex Pharmaceuticals Incorporated (VRTX) and Edwards Lifesciences Corporation (EW).
Vertex (VRTX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
On Vertex's (VRTX) Q1 earnings call, investors will likely focus on the sales performance of its cystic fibrosis medicines and development updates of its non-CF pipeline.
Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $325.15, moving -0.79% from the previous trading session.
Why Vertex (VRTX) Could Beat Earnings Estimates Again
by Zacks Equity Research
Vertex (VRTX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Vertex Pharmaceuticals (VRTX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $326.37, marking a +0.47% move from the previous day.
Is Vertex (VRTX) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Vertex (VRTX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
The Zacks Analyst Blog Highlights bluebird, Oncternal Therapeutics, Avidity, Ascendis and Vertex Pharmaceuticals
by Zacks Equity Research
bluebird, Oncternal Therapeutics, Avidity, Ascendis and Vertex Pharmaceuticals are included in this Analyst Blog.
Biotech Stock Roundup: BLUE Announces Q4 Results, ONCT, ASND & RNA Fall on Updates
by Zacks Equity Research
Earnings and pipeline updates from bluebird bio (BLUE) and Avidity (RNA) are the key highlights for the biotech sector.
CRISPR (CRSP) & Vertex Complete BLA Submission for Exa-Cel
by Zacks Equity Research
CRISPR (CRSP) and Vertex complete BLA submissions to the FDA for exa-cel for treating sickle cell disease and transfusion-dependent beta-thalassemia.
Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $316.33, marking a +0.4% move from the previous day.
Vertex (VRTX) Inks Licensing Deal With CRISPR for Diabetes Drug
by Zacks Equity Research
Vertex Therapeutics (VRTX) enters into a licensing agreement with CRISPR for the latter's gene-editing technology to accelerate the development of its type I diabetes hypoimmune therapy programs.
Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $308.47, marking a -1.88% move from the previous day.